NeuroOne picks former Cardiovascular Systems VP as new COO

NeuroOne Medical Technologies (Nasdaq:NMTC) announced that it appointed Christopher R. Volker as its chief operating officer (COO).

Volker joins the Eden Prairie, Minnesota-based neurotech company from Abbott. He previously served as VP and GM of international at Cardiovascular Systems (CSI), which Abbott acquired earlier this year.

“Chris’ appointment further strengthens our executive leadership team and deepens our capabilities as we build for future commercial growth and expansion into other clinical applications,” said NeuroOne CEO Dave Rosa. “We are excited to benefit from his broad experience in business development, commercial expansion, finance and health economics, and reimbursement.”

NeuroOne commercially launched its Evo sEEG electrode line in the U.S. earlier this year. The electrodes provide up to 30 days of recording, monitoring and stimulation of electrical signals at the subsurface level of the brain.

The company is als…

Read more
  • 0

A veteran Medtronic executive takes a new role at Baxter

Julie Brewer, president of Patient Support Systems, Global Surgical Solutions and Care Communications at Baxter [Image from Brewer’s LinkedIn profile]Medtronic Cardiovascular Diagnostics and Services President Julie Brewer has left for a new position at Baxter.

Brewer announced on LinkedIn near the end of last week that she has joined Baxter (NYSE: BAX) + as President of the Patient Support Systems, Global Surgical Solutions and Care Communications team.

“Baxter is a great company with a wonderful purpose of saving and sustaining lives,” Brewer said. “I spent the last couple of days meeting many on the team and came away energized and excited about the road ahead.”

Brewer also had positive words about Medtronic (NYSE: MDT) + , where she started as an area VP and rose through the ranks.

“After almost 17 years with Medtronic, I am mov…

Read more
  • 0

Orthofix, SeaSpine announce CFO post-merger

SeaSpine CFO John Bostjancic [Image courtesy of SeaSpine]SeaSpine CFO John Bostjancic will continue as the top financial officer of the to-be-named orthopedic device giant created through a merger with Orthofix.

When the two companies announced their plans to merge last month, they said that Bostjancic’s present boss, SeaSpine CEO Keith Valentine, would be CEO.

“John has been a key leader of SeaSpine dating back to the successful spin-out of the organization in 2015. I am confident his background and experience in the medical device industry, coupled with his cultural influence, will benefit the newly combined company as we continue to grow,” Valentine said in today’s news release.

“I believe John is well positioned to help lead us through the successful integration of the two companies, ensuring accountability across all levels of the organization, as we focus on the key initiatives that will drive growth, scalability and shareholder value.” Read more

  • 0

Intuitive, Acutus Medical veterans join Stereotaxis

Stereotaxis (NYSE:STXS) announced today that it appointed two new vice presidents who both have extensive industry experience.

Frank Van Hyfte will join the St. Louis-based surgical robotics company as VP of Europe, the Middle East and Africa and Tim Glynn will join as VP of market development.

Van Hyfte previously spent more than 15 years at Intuitive Surgical, rising from clinical specialist to director of direct and indirect markets in Europe, the Middle East, India and Africa. He also served in senior commercial leadership roles at Exact Imaging, EDAP TMS and eCential Robotics.

Glynn was most recently VP of business and market development at Acutus Medical. There, he established commercial beachheads in Europe and the U.S. to manage product marketing, physician relationships and business partnerships, Stereotaxis said in a news release. Glynn also served in senior marketing roles at Volcano Corporation.

“We see in Stereotaxis the opportunity t…

Read more
  • 0

Henry Schein names C-level executive to drive e-commerce

Mark Hillebrandt, VP and chief digital revenue officer at Henry Schein [Image courtesy of Henry Schein]Henry Schein (Nasdaq: HSIC) announced today that it’s appointed Mark Hillebrandt to the role of VP and chief digital revenue officer, leading a new Digital Revenue Team to boost e-commerce revenues.

Mark Hillebrandt has held executive roles at Henry Schein since 2018. Previous positions included nearly three years as business leader for Amazon’s professional dental, medical and scientific product categories.

Hillebrandt reports to Brad Connett, CEO of Henry Schein’s North America Distribution Group.

“Our strategic plan includes advancing the use of e-commerce tools to help create an exceptional customer experience,” Connett said in a news release. “Mark is a smart and visionary leader who will drive success for this critical element of our strategy through our current online platform as well as evolutions to come, augmenting and supporting the …

Read more
  • 0

Dentsply CFO Jorge Gomez leaves to assume same role at Moderna

Moderna (Nasdaq:MRNA) announced today that it appointed Jorge Gomez as its new chief financial officer.

Gomez resigned as CFO of Dentsply Sirona (Nasdaq:XRAY), effective May 6, to assume the same role at Cambridge, Massachusetts-based Moderna. He will join effective May 9.

Dentsply Sirona said in a news release that it is initiating a search process to identify its next CFO.

“We thank Jorge for his many contributions since joining Dentsply Sirona in 2019, including strengthening the Finance and IT organizations and enhancing our ESG initiative,” Dentsply Sirona CEO Don Casey said in the release.

Gomez, who served as EVP and CFO at Dentsply since August 2019, spent 13 years at Cardinal Health with his most recent role there also being CFO.

“I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee,” Moderna CEO Stéphane Bancel said in a release. “As we grow and scale …

Read more
  • 0

Report: Two vaccine leaders set to step down from FDA

Two senior vaccine leaders within the FDA are reportedly relinquishing their positions within the administration.

According to a report from Endpoints News, which cites a letter released internally to FDA staff first reported on by BioCentury, Marion Gruber and Phil Krause will depart in the coming months due to frustrations over the delegation of certain decisions within some governing bodies. All this comes amid a critical juncture in the effort to vaccinate the U.S. against COVID-19, with the FDA recently fully authorizing Pfizer and BioNTech’s vaccine and reviewing booster shots, which could be available in September.

Gruber, a 32-year veteran at the FDA and currently the director of the FDA’s Office of Vaccines Research & Review, will leave at the end of October, the report said. Krause, the deputy director of the Office of Vaccines Research & Review, will leave in November.

Endpoints cited a former FDA leader as saying Gruber an…

Read more
  • 0

Thermo Fisher Scientific expands corporate leadership team

Thermo Fisher Scientific (NYSE:TMO) announced today that it appointed Alan Sachs to chief medical officer and Karen E. Nelson to chief scientific officer.

Sachs served as Waltham, Mass.-based Thermo Fisher’s CSO since 2016 and will be succeeded by Nelson as he assumes the newly established CMO position at the company. Both will join the company’s leadership team in August.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Former head of Operation Warp Speed leaves two more drug companies

Following allegations of sexual harassment, former head of Operation Warp Speed Moncef Slaoui has left roles at two more companies.

Yesterday, Slaoui was terminated as the chair of the Galvani board of directors, GlaxoSmithKline’s board of directors announced. The same day, Vaxcyte confirmed in an SEC filing that it had axed Slaoui as its chairman of the board. Today, Centessa Pharmaceuticals announced that he stepped down as the company’s chief scientific officer.

Slaoui, who served as the head of Operation Warp Speed — the Trump administration’s program to accelerate COVID-19 vaccine development — had his termination made effective immediately by all three companies.

Termination of Slaoui follows the receipt of a letter by GlaxoSmithKline alleging against him sexual harassment and inappropriate conduct towards a GSK employee. The allegations refer to incidents that occurred several years ago when he was a GSK employee.


Read more
  • 0